Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul 21;3(7):2291-2321.
doi: 10.3390/ph3072291.

Nonsteroidal Anti-Inflammatory Drugs and the Kidney

Walter H Hörl  1
Affiliations
Review

Nonsteroidal Anti-Inflammatory Drugs and the Kidney

Walter H Hörl. Pharmaceuticals (Basel). .

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the isoenzymes COX-1 and COX-2 of cyclooxygenase (COX). Renal side effects (e.g., kidney function, fluid and urinary electrolyte excretion) vary with the extent of COX-2-COX-1 selectivity and the administered dose of these compounds. While young healthy subjects will rarely experience adverse renal effects with the use of NSAIDs, elderly patients and those with co-morbibity (e.g., congestive heart failure, liver cirrhosis or chronic kidney disease) and drug combinations (e.g., renin-angiotensin blockers, diuretics plus NSAIDs) may develop acute renal failure. This review summarizes our present knowledge how traditional NSAIDs and selective COX-2 inhibitors may affect the kidney under various experimental and clinical conditions, and how these drugs may influence renal inflammation, water transport, sodium and potassium balance and how renal dysfunction or hypertension may result.

Keywords: acute renal failure; celecoxib; chronic kidney disease; cyclooxygenase; non-steroidal anti-inflammatory drugs.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J. Rheumatol. 1999;56:18–24. - PubMed
    1. Gambaro G., Perazella M.A. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J. Intern. Med. 2003;253:643–652. - PubMed
    1. Sandhu G.K., Heyneman C.A. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann. Pharmacother. 2004;38:700–704. - PubMed
    1. Harris R.C. COX-2 and the Kidney. J. Cardiovasc Pharmacol. 2006;47:S37–S42. - PubMed
    1. de Leval X., Hanson J., David J.L., Masereel B., Pirotte B., Dogné J.M. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr. Med. Chem. 2004;11:1243–1252. - PubMed